Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma
A. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, M. Hedlund, A. S. Hörstedt, R. Brander (Melbourne, Adelaide, Elizabeth Vale, Nedlands, Sydney, Australia; Lund, Sweden)
Source: Annual Congress 2002 - Asthma - Therapy and management -3
Session: Asthma - Therapy and management -3
Session type: Thematic Poster Session
Number: 437
Disease area: Airway diseases
Abstract Aim: To study the efficacy and safety of formoterol (F) (Oxis® Turbuhaler®) as rescue medication in acute severe asthma. Seventy-eight emergency room patients (26 men; mean age 37 years, range 18-69; FEV1 >30% predicted; pulse >=100 beats/min for patients >=50 years of age) were randomized in a double-blind, double-dummy study to receive 18+18 μg of F (delivered doses) or 800+800 μg of salbutamol pMDI via spacer (S) at times 0 and 30 min. Patients were monitored for 4 hours. Mean baseline FEV1 was 1.83 L (59% predicted normal; range, F 31-101% and S 30-107%). Results: Increases in FEV1 from baseline to 45 min were: +10% F and +12% S-treated patients (p=0.73). Max FEV1 increased by 20% in both groups (p=0.98) and average FEV1 over 4 hours by 14% (F) and 13% (S) (p=0.82). S caused numerically but not statistically significant, more systemic β2 -agonist activities than F. Twenty-two patients (28%) discontinued; 8 due to AEs (3 F and 5 S). Conclusion: Oxis® Turbuhaler® 36 μg was well tolerated and as safe and effective as 1600 μg salbutamol by pMDI and plus spacer in patients with acute severe asthma.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, M. Hedlund, A. S. Hörstedt, R. Brander (Melbourne, Adelaide, Elizabeth Vale, Nedlands, Sydney, Australia; Lund, Sweden). Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma. Eur Respir J 2002; 20: Suppl. 38, 437
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006
Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents Source: Eur Respir J 2003; 22: Suppl. 45, 445s Year: 2003
Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020 Year: 2021
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Formoterol and budesonide/formoterol are both equally as fast and effective as salbutamol in relieving severe acute bronchospasm Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001